All In Biotech

Drug Trial Radar · NCT03917472

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Last checked: Nov 20, 2026Latest source record: Aug 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Jul 17, 2019

Primary completion

Mar 24, 2021

Study completion Mar 24, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • BrolucizumabDrug

    Intravitreal injection

  • AfliberceptDrug

    Intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52Time frame: Baseline, Week 52

Locations

92 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Campbell, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Huntington Beach, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Mountain View, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Pasadena, California

  • Novartis Investigative Site

    Poway, California

  • Novartis Investigative Site

    Rancho Cordova, California

  • Novartis Investigative Site

    Redlands, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Santa Barbara, California

  • Novartis Investigative Site

    Torrance, California

  • Novartis Investigative Site

    Ventura, California

  • Novartis Investigative Site

    Altamonte Springs, Florida

  • Novartis Investigative Site

    Deerfield Beach, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Fort Myers, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Pinellas Park, Florida

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Marietta, Georgia

  • Novartis Investigative Site

    ‘Aiea, Hawaii

  • Novartis Investigative Site

    Bloomington, Illinois

  • Novartis Investigative Site

    Oak Forest, Illinois

  • Novartis Investigative Site

    Springfield, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    New Albany, Indiana

  • Novartis Investigative Site

    West Des Moines, Iowa

  • Novartis Investigative Site

    Leawood, Kansas

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.